United States of America
He has worked in the UK, US and Sweden.From 2011 he led the internalisation, development, and integration of AstraZeneca’s mass spectrometry imaging capability, bringing new insights to projects about drug distribution in relation to biological effects. In 2016 he left AstraZeneca and now works as an independent consultant, supporting Biotech and Pharma.
He has worked in the UK, US and Sweden. His particular areas on interest include prediction of Pharmacokinetic properties, physicochemical properties as determinants of drug clearance and distribution, and the use of PKPD modelling to help understand therapeutic utility.